Eli Lilly (LLY) is taking legal action against makers of off-brand versions of its blockbuster diabetes and weight-loss drugs ...
The Trump administration’s cuts to a global AIDS relief program threaten to upend rollout of a groundbreaking HIV prevention ...
Craig Primack stated in part: “In my experience of treating thousands of people, lasting results come from focusing on the individual, not just the condition. This simple belief has shaped the way ...
Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 ...
The study finds better A1c lowering and weight reduction, but an expert clinician says practical issues may pose barriers.
Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...
Eli Lilly is escalating its legal push to protect the exclusivity of its high-profile weight-loss and diabetes drugs, ...
Investor's Business Daily on MSN3d
Hims Dives After Its Lilly-Rivaling Obesity Plan Faces An Unexpected HitchHims stock reversed lower Wednesday as analysts laid out low expectations for Him & Hers' branded tirzepatide.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback